illuminem logo
illuminem logo
  • Rankings
  • Use Cases
  • Pricing
  • Media
  • More
illuminem logo

About illuminem

AboutCareersBecome a Thought Leader

Advertising

Advertise with usPromote EventsOur Reach

Support

FAQsContact Us
Terms & Privacy Policy

© 2026 illuminem. All rights reserved. Various trademarks held by their owners.

  1. Home
  2. ›
  3. Industries
  4. ›
  5. health care
  6. ›
  7. Mesoblast
Company logo

Mesoblast | Sustainability Performance

https://www.mesoblast.com

A biotechnology company developing regenerative medicine therapies based on proprietary mesenchymal stem cell technology for inflammatory diseases.

2004

Australia

51 - 200 employees

Biotechnology

$10M - 25M in revenue

Not profitable

Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.

Sustainability Ranking & Industry Benchmark

#4797
Overallⓘ
#93
in Australiaⓘ
#104
in Biotechnologyⓘ

Sustainability Maturity

ⓘ
​​0123456789​​%

Sustainability Intent

ⓘ

Available in
Scale package

Access
​​0123456789​​%

Industry Rank

217 out of 244

Overview
Environmental
Digital emissions
Financial Data
Business performanceCapital & innovationAnalyst projections

View similiar companies

Company logo
Neurotech International

Australia, Health Care, Biotechnology

Company logo
Starpharma

Australia, Health Care, Biotechnology

Company logo
CSL

Australia, Health Care, Biotechnology

Market cap ⓘTotal market value of the company's outstanding shares, calculated by multiplying the share price by the number of shares outstanding.
1.8B$, 2026▼23.2% YoY
Revenue ⓘTotal revenue reported in the company's financial statements for the specified reporting year, reflecting income generated from primary business activities. Expressed in millions of USD.
17.0M$, 2025▼70.6% YoY
R&D intensity ⓘResearch and development expenditure expressed as a percentage of revenue, reflecting the company's relative investment in innovation.
200%2025

Controversy level

Very Low
Low
Noticeable
High
Severe
Download Controversy Analysis
  • Mesoblast's cell therapies faced FDA review challenges regarding clinical evidence.
Powered by illuminem

Reporting

sustainability report symbol

Sustainability Report

 Available

Sustainability employees

ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.

Total sustainability employees

1

ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.

    Available in
    Scale package

    Access
  • Email
  • Email